Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma Group International has announced a supplemental notice for its Annual General Meeting scheduled for May 19, 2025, in Suzhou, China. The meeting will address additional resolutions concerning amendments to the company’s RSU Schemes and Share Option Scheme, as well as the approval of limits on shares issued under these schemes. These resolutions are significant for the company’s governance and could impact its operational strategies and stakeholder interests.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing therapies for cancer, hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and operates primarily in the pharmaceutical industry, with a market focus on innovative drug development.
YTD Price Performance: 8.58%
Average Trading Volume: 4,255,328
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.04B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.